Different Outcome in Node-positive Breast Cancer Patients Found by Axillary Ultrasound or Sentinel Node Procedure
Overview
Affiliations
Background: The Z0011 trial initiated a paradigm shift in the axillary treatment of breast cancer patients with a positive sentinel lymph node biopsy (SLNB), disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). We examined whether relevant differences exist between these patients to determine if the conclusions of the ACOSOG Z0011 trial are applicable to UGLNB-positive patients.
Methods: Patients diagnosed with invasive breast cancer in the Netherlands between January 2008 and December 2014 were selected from the Netherlands Cancer Registry.
Results: A total of 11,820 cases were included: 9149 cases in the SLNB group and 2671 in the UGLNB group. Multivariate analyses showed that UGLNB-positive patients were older (p < 0.001), more likely to have a poorly differentiated tumor (p < 0.001), had a negative hormone receptor status (p < 0.001), and more often had extensive nodal involvement (p < 0.001). However, they were less likely to undergo adjuvant radiation (p = 0.004) or systemic therapy (p < 0.001). Even after adjusting for these factors, UGLNB-positive patients had a worse overall survival (HR = 1.38; 95% CI 1.23-1.56) than SLNB-positive patients.
Conclusion: This nationwide retrospective study shows that young patients found positive by UGLNB have less favorable disease characteristics and a worse prognosis compared to patients with a positive SLNB. Selection by ultrasound plays an important role when axillary treatment strategies are considered. Hence, the conclusions of the Z0011 trial cannot unconditionally be applied to patients with a positive UGLNB.
Tvedskov T, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J Lancet Reg Health Eur. 2024; 47:101083.
PMID: 39386258 PMC: 11460525. DOI: 10.1016/j.lanepe.2024.101083.
Axillary surgery in oncologic breast surgery: a narrative review.
Tvedskov T Gland Surg. 2024; 12(12):1774-1785.
PMID: 38229843 PMC: 10788576. DOI: 10.21037/gs-23-362.
Man V, Luk W, Fung L, Kwong A Breast Cancer Res Treat. 2022; 196(2):245-254.
PMID: 36138294 DOI: 10.1007/s10549-022-06699-w.
Sentinel Lymph Node Mapping in Breast Cancer: Initial Experience of a Multidisciplinary Team.
Yasmin T, Younis M, Masood M, Khan H, Asgher Z, Shahid A Cureus. 2022; 14(6):e25983.
PMID: 35859965 PMC: 9286901. DOI: 10.7759/cureus.25983.
Luan T, Li Y, Wu Q, Wang Y, Huo Z, Wang X Breast J. 2022; 2022:6483318.
PMID: 35711901 PMC: 9187279. DOI: 10.1155/2022/6483318.